Global Exocrine Pancreatic Insufficiency Treatment Market Research Report By Treatment Type (Enzyme Replacement Therapy, Pancreatic Enzyme Inhibitors, Other Therapies), By Indication (Cystic Fibrosis, Chronic Pancreatitis, Pancreatic Cancer, Other Indications), By Route of Administration (Oral, Intravenous, Subcutaneous), By Strength (Low Dose, Medium Dose, High Dose), By Formulation (Capsules, Tablets, Injections, Solutions) and By Regional (North America, Europe, South America, Asia Pacific, Middle East and Africa) - Forecast to 2032

Global Exocrine Pancreatic Insufficiency Treatment Market Overview

As per MRFR analysis, the Exocrine Pancreatic Insufficiency Treatment Market Size was estimated at 8.74 (USD Billion) in 2022.

The Exocrine Pancreatic Insufficiency Treatment Market Industry is expected to grow from 9.23 (USD Billion) in 2023 to 15.2 (USD Billion) by 2032. The Exocrine Pancreatic Insufficiency Treatment Market CAGR (growth rate) is expected to be around 5.69% during the forecast period (2024 - 2032).

Key Exocrine Pancreatic Insufficiency Treatment Market Trends Highlighted

The global Exocrine Pancreatic Insufficiency Treatment market is driven by factors such as increasing prevalence of chronic pancreatitis and pancreatic cancer, growing demand for enzyme replacement therapy, and rising awareness about the condition. Furthermore, key market trends include advancements in pancreatic enzyme formulations, development of novel therapies, and increasing healthcare expenditure in emerging markets. Opportunities to be explored include partnerships with patient advocacy groups, investment in research and development of new treatments, and expansion into untapped markets.

In recent times, the market has witnessed a shift towards personalized medicine, with the development of tailored treatment plans based on individual patient needs. Additionally, technological advancements such as telemedicine and remote patient monitoring are enhancing access to care and improving patient outcomes.

Source: Primary Research, Secondary Research, MRFR Database and Analyst Review

Exocrine Pancreatic Insufficiency Treatment Market Drivers

Increasing Prevalence of Chronic Pancreatitis and Cystic Fibrosis

Chronic pancreatitis and cystic fibrosis are two of the most prevalent factors resulting in exocrine pancreatic insufficiency. Chronic pancreatitis refers to the persistent inflammation within the pancreas, which is likely to cause damage to the organ such that it produces fewer and lower-quality enzymes. On the other hand, cystic fibrosis is a genetic disorder that leads to the secretion of thick, stickier mucus. This mucus blocks the pancreatic ducts that carry enzymes to the small intestine, reducing the number of enzymes that reach the small intestine.

The increasing prevalence of this condition is expected to drive the demand for exocrine pancreatic insufficiency treatments over the forecast period. According to the National Pancreas Foundation, there are approximately 80,000 people in the United States who have chronic pancreatitis. Meanwhile, the Cystic Fibrosis Foundation estimates that there are 30,000 people with CF in the United States. However, these estimates are expected to increase in the years to come due to the aging population and the increasing incidence of obesity.

Growing Awareness of Exocrine Pancreatic Insufficiency

Exocrine pancreatic insufficiency is a relatively common condition; however, it is typically undiagnosed or misdiagnosed. It is undiagnosed because the symptoms are practically the same as in other conditions, such as irritable bowel syndrome and celiac disease, and misdiagnosed because testing for EPI is complicated and expensive. In the last couple of years, there has been an increase in the number of people aware of the disease, resulting in more people getting the proper diagnosis.

It is expected that the trend will positively influence demand for exocrine pancreatic insufficiency treatments over the forecast period.

Development of New and Improved Treatment Options

Moreover, over the forecast period, the growth of the exocrine pancreatic insufficiency market will be facilitated by the emergence of new, better treatment options. In recent years, several drugs have been approved for the treatment of exocrine pancreatic insufficiency. These new drugs are more effective and have fewer adverse effects, which is likely to facilitate growth of the exocrine pancreatic insufficiency market. Apart from that, a number of drug delivery systems are currently developed by different pharmaceutical companies.

These drug delivery forms can facilitate the administration of the drugs and can be more convenient for the patients. In their turn, new treatments are likely to bring this condition under better control, and the overall demand is expected to increase in the next decade.

Exocrine Pancreatic Insufficiency Treatment Market Segment Insights

Exocrine Pancreatic Insufficiency Treatment Market Treatment Type Insights

The global exocrine pancreatic insufficiency treatment market is segmented by treatment type into enzyme replacement therapy, pancreatic enzyme inhibitors, and other therapies. Among these segments, enzyme replacement therapy held the largest market share of around 75% in 2023 and is forecast to remain dominant throughout the review period. The high prevalence of exocrine pancreatic insufficiency and the increasing adoption of enzyme replacement therapy as the first line of treatment are the primary factors driving the growth of this segment. Pancreatic enzyme inhibitors, on the other hand, accounted for approximately 15% of the market share as of 2023.

These drugs are primarily used in combination with enzyme replacement therapy to improve the effectiveness of the treatment. The increasing use of combination therapies is projected to drive the growth of this segment. Other therapies, however, had a market share of around 10% in 2023. These therapies are primarily drug classes, including proton pump inhibitors and histamine-2 receptor antagonists, that help manage the condition and have become more popular because they can relieve symptoms of exocrine pancreatic insufficiency and improve the quality of life.

The overall global exocrine pancreatic insufficiency treatment market is forecast to expand at a CAGR of about 5.5% during the review period, reaching a market size of around USD 10.5 billion by the end of 2024, propelling the growth of this segment. Factors such as the increasing prevalence of exocrine pancreatic insufficiency, the rising use of enzyme replacement therapy, and the growing use of combination therapies are projected to enhance the growth of this market.

Global Exocrine Pancreatic Insufficiency Treatment Market, by Treatment Type 2023 & 2032 (USD Billion)

Source: Primary Research, Secondary Research, MRFR Database and Analyst Review

Exocrine Pancreatic Insufficiency Treatment Market Indication Insights

The Global Exocrine Pancreatic Insufficiency Treatment Market segmentation by Indication comprises Cystic Fibrosis, Chronic Pancreatitis, Pancreatic Cancer, and Other Indications. Among these, Cystic Fibrosis held the largest share of the market in 2023, accounting for around 42.6%, and is projected to continue its dominance throughout the forecast period. Cystic Fibrosis is a prevalent genetic disorder that affects the exocrine glands, leading to thick and sticky mucus that obstructs the pancreatic ducts, hindering the release of digestive enzymes.

Consequently, individuals with Cystic Fibrosis rely on Exocrine Pancreatic Insufficiency Treatment to replenish the missing enzymes, aiding in digestion and nutrient absorption.

Exocrine Pancreatic Insufficiency Treatment Market Route of Administration Insights

The Global Exocrine Pancreatic Insufficiency Treatment Market segmentation by Route of Administration includes Oral, Intravenous, and Subcutaneous. Orally administered medications hold the largest market share. The ease of administration, cost-effectiveness, and the availability of a wide range of medications in oral dosage forms drive the segment's growth. The Global Exocrine Pancreatic Insufficiency Treatment Market data shows that the oral segment is projected to maintain its dominance throughout the forecast period. Intravenous administration is preferred in emergency situations or when patients are unable to take oral medications.

Subcutaneous administration is less common but offers advantages such as sustained drug delivery and reduced side effects. The Global Exocrine Pancreatic Insufficiency Treatment Market revenue for the oral segment was valued at USD 4.5 billion in 2023 and is expected to reach USD 7 billion by 2032. The Intravenous segment is expected to grow at a CAGR of 4.5% during the forecast period.

Exocrine Pancreatic Insufficiency Treatment Market Strength Insights

Market research suggests that within the Global Exocrine Pancreatic Insufficiency Treatment Market, the Strength segment plays a significant role. By analyzing recent Global Exocrine Pancreatic Insufficiency Treatment Market segmentation data, it has been observed that the Strength segment is further divided into three sub-segments: Low Dose, Medium Dose, and High Dose. In 2023, the Low Dose sub-segment held the largest share of the Global Exocrine Pancreatic Insufficiency Treatment Market revenue, capturing around 45% of the total market. This dominance can be attributed to its cost-effectiveness and wide acceptance among healthcare professionals.

The Medium Dose sub-segment is anticipated to experience the highest growth rate over the forecast period, owing to its increasing adoption for moderate cases of exocrine pancreatic insufficiency. The High Dose sub-segment, although having a smaller market share, is also expected to witness steady growth due to its effectiveness in treating severe cases.

Exocrine Pancreatic Insufficiency Treatment Market Formulation Insights

The Global Exocrine Pancreatic Insufficiency Treatment Market is segmented based on formulation into capsules, tablets, injections, and solutions. In 2023, the capsules segment held the largest market share, accounting for around 45% of the global market revenue. The large share of the capsule segment can be attributed to the ease of administration and the availability of a wide range of capsule-based formulations. The tablets segment is expected to witness significant growth during the forecast period, owing to the increasing adoption of combination therapies that include tablets.

The injections segment is expected to grow at a steady pace, driven by the rising demand for injectable formulations in hospital settings. The solutions segment is anticipated to experience moderate growth due to the limited availability of solution-based formulations for exocrine pancreatic insufficiency treatment.

Exocrine Pancreatic Insufficiency Treatment Market Regional Insights  

The Global Exocrine Pancreatic Insufficiency Treatment Market is segmented into North America, Europe, APAC, South America, and MEA. North America is the largest market for exocrine pancreatic insufficiency treatment, accounting for over 40% of the global market revenue in 2023. This is due to the high prevalence of chronic pancreatitis and other conditions that lead to exocrine pancreatic insufficiency in the region. Europe is the second largest market, followed by APAC. APAC is expected to grow at the fastest rate over the forecast period due to the increasing incidence of diabetes and other chronic diseases in the region.

South America and MEA are relatively smaller markets, but they are also expected to grow at a steady pace over the forecast period.

Global Exocrine Pancreatic Insufficiency Treatment Market, by Region 2023 & 2032 (USD Billion)

Source: Primary Research, Secondary Research, MRFR Database and Analyst Review

Exocrine Pancreatic Insufficiency Treatment Market Key Players And Competitive Insights

Major players in the Exocrine Pancreatic Insufficiency Treatment Market industry are continuously striving to improve their product offerings and expand their market reach. Leading Exocrine Pancreatic Insufficiency Treatment Market players are investing in research and development to innovate new and effective treatments for patients suffering from this condition. The Exocrine Pancreatic Insufficiency Treatment Market is expected to witness significant growth in the coming years due to the increasing prevalence of chronic pancreatitis and cystic fibrosis, as well as rising awareness about the condition. Companies in the Exocrine Pancreatic Insufficiency Treatment Market are also focusing on strategic partnerships and collaborations to enhance their market position and gain access to new technologies and markets. Overall, the Exocrine Pancreatic Insufficiency Treatment Market is highly competitive, with key players vying for market share through innovation, strategic alliances, and geographical expansion.

A leading player in the Exocrine Pancreatic Insufficiency Treatment Market is AbbVie Inc. The company offers a range of treatments for patients with exocrine pancreatic insufficiency and related conditions. AbbVie Inc. has a strong global presence and a large portfolio of products, including enzymes, nutritional supplements, and anti-inflammatory medications. The company is committed to providing innovative and effective treatments for patients suffering from exocrine pancreatic insufficiency. With their focus on research and development, AbbVie Inc. is well-positioned to continue to be a leader in the Exocrine Pancreatic Insufficiency Treatment Market.

A competitor company in the Exocrine Pancreatic Insufficiency Treatment Market is Allergan plc. The company offers a range of products for the treatment of exocrine pancreatic insufficiency, including enzymes, nutritional supplements, and antacids. Allergan plc has a strong presence in Europe and North America and is expanding its reach into Asia and Latin America. The company is focused on developing new and innovative treatments for patients with exocrine pancreatic insufficiency and related conditions. Allergan plc is investing in research and development to enhance its product portfolio and meet the evolving needs of patients. With their commitment to innovation and a patient-centric approach, Allergan plc is well-positioned to compete in the Exocrine Pancreatic Insufficiency Treatment Market.

Key Companies in the Exocrine Pancreatic Insufficiency Treatment Market Include:

• Horizon Therapeutics


• Halozyme Therapeutics


• Reddy's Laboratories


• Theravance Biopharma


• Evotec SE


• Johnson Johnson


• Roche


• Novo Nordisk


• S. WorldMeds


• Zealand Pharma


• Axcella Health


• Cumberland Pharmaceuticals


• Shire


• Mallinckrodt


• AbbVie

Exocrine Pancreatic Insufficiency Treatment Market Industry Developments

The global Exocrine Pancreatic Insufficiency Treatment Market is anticipated to reach USD 15.2 billion by 2032, expanding at a CAGR of 5.69% from 2024 to 2032. Rising prevalence of chronic pancreatitis, cystic fibrosis, and pancreatic cancer is driving the market growth. Moreover, increasing awareness about enzyme replacement therapy (ERT) and advancements in drug delivery systems are fueling market expansion. Key players include AbbVie, Johnson Johnson, and Chiesi Farmaceutici.

Recent developments include the launch of Creon (pancrelipase) by AbbVie in 2023, offering a convenient and effective treatment option for EPI patients. Additionally, the FDA approval of Viokace (pancrelipase) in 2022 provides a novel treatment option with improved tolerability and efficacy. Furthermore, the development of novel drug delivery systems, such as microspheres and nanoparticles, is expected to enhance drug delivery and improve patient outcomes, driving market growth in the coming years.

Exocrine Pancreatic Insufficiency Treatment Market Segmentation Insights

Exocrine Pancreatic Insufficiency Treatment Market Treatment Type Outlook

• Enzyme Replacement Therapy


• Pancreatic Enzyme Inhibitors


• Other Therapies

Exocrine Pancreatic Insufficiency Treatment Market Indication Outlook

• Cystic Fibrosis


• Chronic Pancreatitis


• Pancreatic Cancer


• Other Indications

Exocrine Pancreatic Insufficiency Treatment Market Route of Administration Outlook

• Oral


• Intravenous


• Subcutaneous

Exocrine Pancreatic Insufficiency Treatment Market Strength Outlook

• Low Dose


• Medium Dose


• High Dose

Exocrine Pancreatic Insufficiency Treatment Market Formulation Outlook

• Capsules


• Tablets


• Injections


• Solutions

Exocrine Pancreatic Insufficiency Treatment Market Regional Outlook

• North America


• Europe


• South America


• Asia Pacific


• Middle East and Africa